AbCellera named one of Canada’s top growing companies
Read More ❯
Pascal Biosciences discovers cannabinoids activate the major histocompatibility complex to aid cancer treatment
Read More ❯
A transition to translation: Dr. Carl Hansen
Read More ❯
AbCellera wins 2019 Technology Impact Award for Company of the Year – Scale Success
Read More ❯
UBC cancer research supported by newly-developed partnership between Pascal Biosciences and Mitacs
Read More ❯
MSL research group spins-out an industry-leading biotechnology company
Read More ❯
AbCellera is growing!
Read More ❯
Microbiome Insights receives funding from the Government of Canada to develop new microbiome testing platform for managing chronic disease
Read More ❯
Tackling the world’s deadliest diseases one Ab at a time: an interview with Dr. Carl Hansen
Read More ❯
AbCellera is enabling the translation of laboratory research to clinical application for fibrosis associated with congenital degenerative diseases
Read More ❯
Vedanta Biosciences receives award from the Crohn’s & Colitis Foundation to advance a microbiome-derived therapeutic program
Read More ❯
Pascal Biosciences receives DEA Schedule I License for cannabinoid development and renews UBC collaboration
Read More ❯